대사 기반 암 치료제 시장(제2판) : 치료법 유형별, 투여 경로별, 대상 질환 및 적응증별, 지역별 내역 및 치료제 판매량 예측 - 동향과 예측(2026-2035년)

Cancer Metabolism Based Therapeutics Market: Overview

As per Roots Analysis, the cancer metabolism based therapeutics market is estimated to grow from USD 3.7 billion in the current year to USD 26.3 billion by 2035, at a CAGR of 24.3% during the forecast period, till 2035.

Cancer Metabolism Based Therapeutics Market: Growth and Trends

Cancer continues to represent a major global health burden, impacting millions of individuals annually. The progression and proliferation of cancer cells are driven by metabolic reprogramming, a process that enables these cells to utilize nutrients differently from normal cells. This reprogramming is characterized by alterations in key metabolic pathways, including elevated glucose absorption (associated with the Warburg effect), impaired mitochondrial function, and increased reliance on nutrients such as glutamine and lipids. These changes collectively define the distinct metabolic profile of cancer cells compared to healthy cells.

In the mid-20th century, the seminal work of Otto Warburg in cancer metabolism demonstrated that tumor tissues preferentially utilize aerobic glycolysis. This discovery catalyzed significant interest among both industry and academic stakeholders in targeting reprogrammed metabolic pathways critical for tumor survival. Subsequently, research efforts have focused on identifying and characterizing key enzymes involved in pathways such as the tricarboxylic acid (TCA) cycle, lipid biosynthesis, and amino acid, pentose phosphate, and nucleotide metabolism.

These foundational insights have driven the development and advancement of cancer metabolism-based therapeutics, which have shown promise in effectively targeting and disrupting tumor-specific metabolic pathways, thereby inhibiting uncontrolled cell proliferation. Supported by encouraging therapeutic outcomes, companies have entered into numerous strategic collaborations to accelerate research and development activities within the global cancer metabolism therapeutics market. As more candidates progress into late-stage clinical development, partnership activity is expected to intensify, supporting robust market growth in the coming years.

Growth Drivers: Strategic Enablers of Market Expansion

The growth of the cancer metabolism-based therapeutics market is being driven by the increasing adoption of precision medicine approaches that target the distinct metabolic pathways associated with individual tumor profiles, enabling the development of more personalized and effective treatment strategies. This shift is encouraging pharmaceutical companies to expand their research and development pipelines to address the rising demand for targeted cancer therapies. At the same time, the global cancer burden continues to increase significantly, with approximately 20 million new cases and over 10 million deaths reported in a single year, and projections suggesting that annual incidence could exceed 35 million cases by 2050 due to population growth and demographic trends. This escalating prevalence underscores the urgent need for innovative therapeutic solutions, such as cancer metabolism-based therapies, which focus on reprogrammed metabolic pathways in cancer cells and offer improved efficacy and a higher degree of personalization compared to conventional treatment approaches.

Market Challenges: Critical Barriers Impeding Progress

The cancer metabolism-based therapeutics market faces significant challenges due to limitations in target specificity and the inherent complexity of tumor metabolism. Many existing therapies demonstrate suboptimal target specificity and elevated toxicity, as cancerous and healthy cells often share overlapping metabolic pathways, leading to off-target effects. These issues contribute to high clinical trial failure rates, limited regulatory approvals, increased development costs, and constrained commercial viability. Furthermore, the metabolic plasticity of cancer cells presents an additional hurdle, enabling them to dynamically adapt to microenvironmental stresses such as nutrient deprivation and hypoxia. This adaptability complicates efforts to effectively target a single metabolic pathway, given the highly heterogeneous and flexible nature of tumor metabolism. As a result, conventional treatments such as chemotherapy and radiation therapy yield variable outcomes and are effective only in a subset of patients, owing to differences in genetic mutations and protein expression profiles. This variability underscores the critical need for advancing precision and personalized therapeutic approaches in oncology.

Cancer Metabolism Based Therapeutics Market: Key Insights

The report delves into the current state of the cancer metabolism based therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Currently, close to 250 cancer metabolism-based therapy programs are exploiting the unique metabolic vulnerabilities of tumor cells for targeting a wide range of cancer disease indications.

• Close to 90% of the cancer metabolism-based therapy programs are in clinical stages; majority (52%) of these programs are being investigated in phase II clinical trials.
• A sizeable proportion of the trials (~30%) were registered in 2025; over 70% of the trials are currently recruiting potential candidates for the investigation of cancer metabolism-based therapies.
• Around 65% of the agreements in the cancer metabolism-based therapies market were inked in the last two years; notably, majority (>50%) of the deals were inked by players headquartered in North America.

• Growing cancer burden, advancements in targeted therapies and increasing funding in R&D activities is driving market growth.
• Owing to the rising prevalence of cancer along with significant advances in tumor metabolism research, the global cancer metabolism-based therapies market is anticipated to grow at a CAGR of 24.3% till 2035.

• The cancer metabolism-based therapies market in the US is expected to grow at a steady CAGR during the forecast period, due to the expanding clinical use and growing adoption of cancer metabolism-based therapies.
• Owing to the presence of established market players, rapid increase in patients diagnosed with cancer, along with ongoing technological advancements, the cancer metabolism-based therapeutics market in the US is expected to witness substantial growth.

Cancer Metabolism based Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Modality

• Small Molecules
• Biologics

By Route of Administration

• Oral
• Intravenous
• Intramuscular

By Target Disease Indication

• Breast Cancer
• Non-small Cell Lung Cancer
• Acute Myeloid Leukemia
• Brain Cancer
• Cholangiocarcinoma
• Bile Duct Cancer
• Myelodysplastic Syndromes
• Malignant-mesothelioma
• Soft Tissue Sarcoma
• Hepatocellular Carcinoma
• Pancreatic Cancer

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

By Sales Forecast of Therapies

• Daraxonrasib
• Gedatolisib
• Olomorasib
• Inavolisib
• Vorasidenib
• STX-478
• AZD 5363
• AG-120
• Selpercatinib
• ADI-PEG 20
• Augtyro
• Taletrectinib
• Piqray
• TAS-120
• Rezlidhia
• AG-221

Cancer Metabolism Based Therapeutics Market: Key Segments

Which Route of Administration Accounts for the Largest Cancer Metabolism Based Therapeutics Market Share?

By 2035, the oral route of administration segment is expected to account for the largest share of the market, capturing approximately 85%, while also demonstrating strong growth throughout the forecast period. This dominance can be attributed to its non-invasive nature, ease of administration, and higher patient compliance compared to alternative delivery routes. Meanwhile, the intramuscular segment is projected to register a higher compound annual growth rate (CAGR), driven by its ability to enable controlled and sustained release of metabolic inhibitors over extended durations, thereby maintaining stable therapeutic drug levels and reducing dosing frequency.

Which Type of Modality Accounts for the Largest Share?

Based on market analysis, the small molecules segment is expected to capture the largest share of the Cancer Metabolism based Therapeutics Market by 2035. This dominance is driven by their demonstrated efficacy, ease of administration, cost-effective manufacturing, and well-established safety profiles.

Regional Market Analysis: Which Regions are Showing the Fastest Growth?

North America: Largest Regional Market

North America is projected to account for over 45% of the global market share by 2035, driven by the increasing demand for cancer metabolism-based therapies in the United States and the strong presence of established therapy developers in the region. Additionally, several leading manufacturers have expanded their development and production capabilities in recent years to address the growing regional demand.

Asia-Pacific: Fastest Growing Regional Market

The Asia-Pacific market in Cancer Metabolism based Therapeutics Market is anticipated to register a higher CAGR through 2035, supported by increasing investments in research and development of novel cancer metabolism-based therapies and regulatory frameworks that favor developers with specialized capabilities. Additionally, the region's expanding patient population is enlarging the addressable market for pharmaceuticals and healthcare products, thereby driving overall market growth.

Example Players in Cancer Metabolism based Therapeutics Market

• Bristol Myers Squibb
• Eli Lilly
• Novartis
• Polaris
• Roche

Cancer Metabolism Based Therapeutics Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the Cancer Metabolism based Therapeutics Market, focusing on key market segments, including [A] type of modality, [B] route of administration, [C] target disease indication, [D] geographical regions, and [E] sales forecast of therapies.
• Cancer Metabolism-Based Therapies Market Landscape: A detailed assessment of the overall cancer metabolism-based therapies market landscape, along with information on several relevant parameters, such as [A] metabolic pathway, [B] target, [C] target disease indication, [D] route of administration, [E] type of modality, [F] type of therapy, [G] drug designation, [H] year of establishment [I] company size, and [J] location of headquarters.
• Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating cancer metabolism-based therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] trial study design, [F] type of sponsor, [G] patient gender, [H] most active industry and non-industry players and [I] geographical distribution.
• Partnerships and Collaborations Analysis: An analysis of the partnerships that have been inked by stakeholders engaged in this domain. It includes a brief description of various partnership models and includes a detailed analysis of partnerships based on [A] year of partnership, [B] type of partnership, and [C] geographical analysis.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

• Which are the leading companies in the Cancer Metabolism based Therapeutics Market?
• Which region dominates the Cancer Metabolism based Therapeutics Market?
• What are the key trends observed in the Cancer Metabolism based Therapeutics Market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by cancer metabolism-based therapeutic developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Overview of Cancer Metabolism-Based Therapies
• 6.2. Key Metabolic Alterations Associated with Cancer Cells
• 6.3. Core Metabolic Pathways Associated with Cancer
• 6.4. Advantages of Cancer Metabolism-Based Therapies
• 6.5. Challenges Associated with Cancer Metabolism-Based Therapies
• 6.6. Future Outlook

7. MARKET LANDSCAPE

• 7.1. Methodology and Key Parameters
• 7.2. Cancer Metabolism-Based Therapies: Overall Market Landscape
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Metabolic Pathway
  • 7.2.3. Analysis by Target
  • 7.2.4. Analysis by Target Disease Indication
  • 7.2.5. Analysis by Route of Administration
  • 7.2.6. Analysis by Type of Modality
  • 7.2.7. Analysis by Type of Therapy
  • 7.2.8. Analysis by Drug Designation
• 7.3. Cancer Metabolism-Based Therapies: Developer Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Company Size and Location of Headquarters
  • 7.3.5. Most Active Players: Analysis by Number of Therapies Developed

8. COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. AstraZeneca
  • 8.2.1. Company Details
  • 8.2.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.2.3. Key Initiatives
• 8.3. Bristol Myers Squibb
  • 8.3.1. Company Details
  • 8.3.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.3.3. Key Initiatives
• 8.4. Cornerstone Pharmaceuticals
  • 8.4.1. Company Details
  • 8.4.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.4.3. Key Initiatives
• 8.5. Eli Lilly
  • 8.5.1. Company Details
  • 8.5.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.5.3. Key Initiatives
• 8.6. Novartis
  • 8.6.1. Company Details
  • 8.6.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.6.3. Key Initiatives
• 8.7. Polaris
  • 8.7.1. Company Details
  • 8.7.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.7.3. Key Initiatives
• 8.8. Roche
  • 8.8.1. Company Details
  • 8.8.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.8.3. Key Initiatives
• 8.9. Servier
  • 8.9.1. Company Details
  • 8.9.2. Cancer Metabolism-Based Drugs Portfolio
  • 8.9.3. Key Initiatives

9. CLINICAL TRIAL ANALYSIS

• 9.1. Methodology and Key Parameters
• 9.2. Cancer Metabolism-Based Therapies: Clinical Trial Analysis
  • 9.2.1. Analysis by Trial Registration Year
  • 9.2.2. Analysis by Trial Status
  • 9.2.3. Analysis by Trial Registration Year and Trial Status
  • 9.2.4. Analysis by Number of Patients Enrolled and Trial Registration Year
  • 9.2.5. Analysis by Number of Patients Enrolled and Trial Status
  • 9.2.6. Analysis by Trial Phase
  • 9.2.7. Analysis by Number of Patients Enrolled and Trial Phase
  • 9.2.8. Analysis by Study Design
    • 9.2.8.1. Analysis by Design Masking
    • 9.2.8.2. Analysis by Type of Intervention Model
    • 9.2.8.3. Analysis by Trial Purpose
    • 9.2.8.4. Analysis by Type of Allocation
  • 9.2.9. Analysis by Type of Sponsor / Collaborator
  • 9.2.10. Analysis by Patient Gender
  • 9.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials
  • 9.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
  • 9.2.13. Analysis by Geography
    • 9.2.13.1. Analysis of Clinical Trials by Trial Status, Trial Phase and Geography
    • 9.2.13.2. Analysis of Clinical Trials by Trial Status and Geography
    • 9.2.13.3. Analysis of Clinical Trials by Patients Enrolled, Trial Status and Geography
  • 9.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
    • 9.2.14.1. Clinical Trials in North America: Key Insights
    • 9.2.14.2. Clinical Trials in Europe: Key Insights
    • 9.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
    • 9.2.14.4. Clinical Trials in Rest of the World: Key Insights

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Partnership Models
• 10.2. Cancer Metabolism-Based Therapies: Partnerships and Collaborations
  • 10.2.1. Analysis by Year of Partnership
  • 10.2.2. Analysis by Type of Partnership
  • 10.2.3. Analysis by Year and Type of Partnership
  • 10.2.4. Analysis by Target Disease Indication
  • 10.2.5. Most Active Players: Analysis by Number of Partnerships
  • 10.2.6. Analysis by Geography
    • 10.2.6.1. Local and International Deals
    • 10.2.6.2. Intercontinental and Intracontinental Deals

11. MARKET IMPACT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Market Drivers
• 11.3. Market Restraints
• 11.4. Market Opportunities
• 11.5. Market Challenges

12. GLOBAL CANCER METABOLISM-BASED THERAPIES MARKET

• 12.1. Forecast Methodology
• 12.2. Key Assumptions
• 12.3. Global Cancer Metabolism-Based Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 12.4. Multivariate Scenario Analysis
  • 12.4.1. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Conservative Scenario
  • 12.4.2. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Optimistic Scenario
• 12.5. Key Market Segmentations

13. CANCER METABOLISM-BASED THERAPIES MARKET, BY TYPE OF MODALITY

• 13.1. Cancer Metabolism-Based Therapies Market: Distribution by Type of Modality
  • 13.1.1. Cancer Metabolism-Based Therapies Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 13.1.2. Cancer Metabolism-Based Therapies Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 13.2. Data Triangulation and Validation

14. CANCER METABOLISM-BASED THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

• 14.1. Cancer Metabolism-Based Therapies Market: Distribution by Route of Administration
  • 14.1.1. Cancer Metabolism-Based Therapies Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 14.1.2. Cancer Metabolism-Based Therapies Market for Intramuscular Route: Forecasted Estimates (Till 2035)
  • 14.1.3. Cancer Metabolism-Based Therapies Market for Intravenous Route: Forecasted Estimates (Till 2035)
• 14.2. Data Triangulation and Validation

15. CANCER METABOLISM-BASED THERAPIES MARKET: BY TARGET DISEASE INDICATION

• 15.1. Cancer Metabolism-Based Therapies Market: Distribution by Target Disease Indication
  • 15.1.1.Cancer Metabolism-Based Therapies Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 15.1.2. Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 15.1.3. Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 15.1.4. Cancer Metabolism-Based Therapies Market for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
  • 15.1.5. Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 15.1.6. Cancer Metabolism-Based Therapies Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 15.1.7. Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 15.1.8. Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
  • 15.1.9. Cancer Metabolism-Based Therapies Market for Pancreatic Cancer: Forecasted Estimates (Till 2035)
  • 15.1.10. Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
  • 15.1.11. Cancer Metabolism-Based Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
• 15.2. Data Triangulation and Validation

16. CANCER METABOLISM-BASED THERAPIES MARKET, BY GEOGRAPHY

• 16.1. Cancer Metabolism-Based Therapies Market: Distribution by Geography
  • 16.1.1. Cancer Metabolism-Based Therapies Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.1.1. Cancer Metabolism-Based Therapies Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.1.2. Cancer Metabolism-Based Therapies Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 16.1.2. Cancer Metabolism-Based Therapies Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.1. Cancer Metabolism-Based Therapies Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.2. Cancer Metabolism-Based Therapies Market in the France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.3. Cancer Metabolism-Based Therapies Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.4. Cancer Metabolism-Based Therapies Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.5. Cancer Metabolism-Based Therapies Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.2.6. Cancer Metabolism-Based Therapies Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 16.1.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.1. Cancer Metabolism-Based Therapies Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.2. Cancer Metabolism-Based Therapies Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.3. Cancer Metabolism-Based Therapies Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.4. Cancer Metabolism-Based Therapies Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.5. Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 16.1.3.6. Cancer Metabolism-Based Therapies Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17. CANCER METABOLISM-BASED THERAPIES MARKET, NORTH AMERICA

• 17.1. Cancer Metabolism-Based Therapies Market in North America: Distribution by Type of Modality
  • 17.1.1. Cancer Metabolism-Based Therapies Market in North America for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.1.2. Cancer Metabolism-Based Therapies Market in North America for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 17.2. Cancer Metabolism-Based Therapies Market in North America: Distribution by Route of Administration
  • 17.2.1. Cancer Metabolism-Based Therapies Market in North America for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2.2. Cancer Metabolism-Based Therapies Market in North America for Intramuscular Route: Forecasted Estimates (Till 2035)
  • 17.2.3. Cancer Metabolism-Based Therapies Market in North America for Intravenous Route: Forecasted Estimates (Till 2035)
• 17.3. Cancer Metabolism-Based Therapies Market in North America: Distribution by Target Disease Indication
  • 17.3.1. Cancer Metabolism-Based Therapies Market in North America for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.3.2. Cancer Metabolism-Based Therapies Market in North America for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.3.3. Cancer Metabolism-Based Therapies Market in North America for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.3.4. Cancer Metabolism-Based Therapies Market in North America for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
  • 17.3.5. Cancer Metabolism-Based Therapies Market in North America for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.3.6. Cancer Metabolism-Based Therapies Market in North America for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 17.3.7. Cancer Metabolism-Based Therapies Market in North America for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.3.8. Cancer Metabolism-Based Therapies Market in North America for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
  • 17.3.9. Cancer Metabolism-Based Therapies Market in North America for Pancreatic Cancer: Forecasted Estimates (Till 2035)
  • 17.3.10. Cancer Metabolism-Based Therapies Market in North America for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
  • 17.3.11. Cancer Metabolism-Based Therapies Market in North America for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

18. CANCER METABOLISM-BASED THERAPIES MARKET, EUROPE

• 18.1. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Type of Modality
  • 18.1.1. Cancer Metabolism-Based Therapies Market in Europe for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.1.2. Cancer Metabolism-Based Therapies Market in Europe for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 18.2. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Route of Administration
  • 18.2.1. Cancer Metabolism-Based Therapies Market in Europe for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.2. Cancer Metabolism-Based Therapies Market in Europe for Intramuscular Route: Forecasted Estimates (Till 2035)
  • 18.2.3. Cancer Metabolism-Based Therapies Market in Europe for Intravenous Route: Forecasted Estimates (Till 2035)
• 18.3. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Target Disease Indication
  • 18.3.1. Cancer Metabolism-Based Therapies Market in Europe for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.3.2. Cancer Metabolism-Based Therapies Market in Europe for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.3.3. Cancer Metabolism-Based Therapies Market in Europe for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.3.4. Cancer Metabolism-Based Therapies Market in Europe for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
  • 18.3.5. Cancer Metabolism-Based Therapies Market in Europe for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.3.6. Cancer Metabolism-Based Therapies Market in Europe for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 18.3.7. Cancer Metabolism-Based Therapies Market in Europe for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.3.8. Cancer Metabolism-Based Therapies Market in Europe for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
  • 18.3.9. Cancer Metabolism-Based Therapies Market in Europe for Pancreatic Cancer: Forecasted Estimates (Till 2035)
  • 18.3.10. Cancer Metabolism-Based Therapies Market in Europe for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
  • 18.3.11. Cancer Metabolism-Based Therapies Market in Europe for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

19. CANCER METABOLISM-BASED THERAPIES MARKET, ASIA-PACIFIC

• 19.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Type of Modality
  • 19.1.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.1.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 19.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Route of Administration
  • 19.2.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intramuscular Route: Forecasted Estimates (Till 2035)
  • 19.2.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intravenous Route: Forecasted Estimates (Till 2035)
• 19.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Target Disease Indication
  • 19.3.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.4. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
  • 19.3.5. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.6. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 19.3.7. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.8. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
  • 19.3.9. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Pancreatic Cancer: Forecasted Estimates (Till 2035)
  • 19.3.10. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
  • 19.3.11. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)

Detailed segment-wise distribution across individual regions is available in supporting excel data packs

20. CANCER METABOLISM-BASED THERAPIES MARKET, SALES FORECAST OF DRUGS

• 20.1. Approved Cancer Metabolism-Based Therapies: Sales Forecast
  • 20.1.1. Daraxonrasib: Sales Forecast
  • 20.1.2. Gedatolisib: Sales Forecast
  • 20.1.3. Olomorasib: Sales Forecast
  • 20.1.4. Inavolisib: Sales Forecast
  • 20.1.5. Vorasidenib: Sales Forecast
  • 20.1.6. STX-478: Sales Forecast
  • 20.1.7. AZD 5363: Sales Forecast
  • 20.1.8. AG-120: Sales Forecast
  • 20.1.9. Selpercatinib: Sales Forecast
  • 20.1.10. ADI-PEG 20: Sales Forecast
  • 20.1.11. Augtyro: Sales Forecast
  • 20.1.12. Taletrectinib: Sales Forecast
  • 20.1.13. Piqray / Vijoice: Sales Forecast
  • 20.1.14. TAS-120: Sales Forecast
  • 20.1.15. Rezlidhia: Sales Forecast
  • 20.1.16. AG-221: Sales Forecast

21. CONCLUDING REMARKS

22. EXECUTIVE INSIGHTS

• 22.1. Chapter Overview
• 22.2. Company A
  • 22.2.1. Company Snapshot
  • 22.2.2. Interview Transcript: Associate Professor
• 22.3. Company B
  • 22.3.1. Company Snapshot
  • 22.3.2. Interview Transcript: Medical Oncologist
• 22.4. Company C
  • 22.4.1. Company Snapshot
  • 22.4.2. Interview Transcript: Associate Professor

23. APPENDIX I: TABULATED DATA

24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS